Class summary at a glance.

Every drug in the Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $55.5Mcombined across class
Total Rx claims: 196K72K unique beneficiaries
Generic mfrs (active): 16across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Valganciclovir

Brand: VALGANCICLOVIR · 169K Part D claims (CY24) · 56K beneficiaries · First FDA approval: 2001-03-29

11 generic mfrs 0 plans require PA

Low NADAC$1.44

→

Avg plan cost$1.73

Part D spend $41.9M 1× spread, current vs floor

Class share

75%

of class CY24 spend

View profile →

Ganciclovir

Brand: Ganciclovir · 28K Part D claims (CY24) · 17K beneficiaries · First FDA approval: 2010-04-30

5 generic mfrs 0 plans require PA

Low NADAC$91.38

→

Avg plan cost$91.38

Part D spend $13.6M 1× spread, current vs floor

Class share

25%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.